About this trial
In order to perform heart surgery, a machine called cardiopulmonary bypass (CPB), or more commonly known as a heart-lung machine, is used to maintain the circulation of oxygenated blood needed by the rest of the body and its organs.
Historically, when a patient is connected to CPB, their body is cooled below the normal body temperature. This is known as hypothermia. This is because scientific studies have previously shown that reduced body temperature lowers metabolism and therefore offers more protection to the brain and other organs due to the reduced oxygen requirement. The evidence supporting this practice, however, has been challenged throughout the history of cardiac surgery, with studies supporting that normothermia, or normal body temperature, is a safe alternative. Despite this, the practice of hypothermia has persisted. Published data from a survey of 139 cardiac surgeons in the United Kingdom showed that 84% still routinely employ hypothermic CPB during surgery.
To assess whether normothermic or hypothermic CPB is safer, a clinical trial requiring a large sample size and high recruitment rates will be required. Therefore, the investigators aim to assess firstly the feasibility of trial recruitment and allocation adherence in this study. 100 adults across 10 different cardiac surgery centres in the United Kingdom will be recruited to a multicentre feasibility randomised controlled trial comparing normothermia (active comparator) against hypothermia (control comparator) during cardiopulmonary bypass in cardiac surgery. This study will also test the ability of the Cardiothoracic Interdisciplinary Research Network (CIRN), a trainee-led research collaborative, to collect pilot data on Major Adverse Cardiac and Cerebrovascular Events (MACCE) using a regulation-approved electronic application HealthBitⓇ. Participants will also be asked to complete quality of life surveys. The results of this study will subsequently inform a large, adequately powered randomised controlled trial for optimal temperature management during CPB.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients (≥ 18 years) scheduled for coronary artery bypass surgery and/or valve replacement/ repair, either in the elective or urgent setting.
European System for Cardiac Operative Risk Evaluation (EuroSCORE) II of 2 or higher.
Able to understand and communicate to provide informed consent.
Able to read and understand the English language.
Disqualifiers
Patients undergoing coronary artery bypass surgery in combination with other procedures including cardiac or vascular procedures that require deep hypothermic arrest.
Patients undergoing emergency or salvage surgery.
Patients undergoing off-pump cardiac surgery.
Patients who are participating in another interventional trial.
Trial design
Parallel
Treatments tested in this trial
Hypothermic Cardiopulmonary Bypass
Procedure/SurgeryMild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
Normothermic Cardiopulmonary Bypass
Procedure/SurgeryNormothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
Treatment groups
Trial outcomes
Primary outcomes
Total number of participants recruited over a 6 month period
The target recruitment rate is 1 participant per week per centre. The feasibility trial will be considered positive if 80% of target met, together with outcome 2.
Adherence rate to allocation
The feasibility trial will be considered positive if 74%\* of target adherence to trial allocation is met, together with outcome 1. \*74% is derived from 80% of target adherence of 92% as per Warm Heart Study
Secondary outcomes
Incidence of 6-week composite endpoint of Major Adverse Cardiac and Cerebrovascular Events (MACCE)
MACCE is defined as any post-operative death, stroke, new intra-aortic balloon pump insertion, new renal replacement therapy, re-operation and major bleeding in this feasibility trial.
Incidence of deep sternal wound infection, with or without treatment
Deep sternal wound infection is defined with at least one of the following criteria: (I) an organism is isolated from culture of mediastinal tissue or fluid (II) evidence of mediastinitis seen intraoperatively (III) presence of chest pain, sternal instability, or fever (\> 38 °C), and purulent drainage from the mediastinum or isolation of organism present in a blood culture or from the mediastinal area.
Incidence of all adverse events
Composite of all reported adverse events. Examples of adverse events include: low cardiac output, suspected myocardial infarction, arrhythmias, infections, haemorrhage, and pulmonary embolus.
Critical care length of stay
Number of days a participant is admitted in cardiac critical care unit
Other outcomes
Data completeness
Data recorded on HealthBitⓇ will be assessed for percentage of completion
Attrition rate
For ascertainment of the primary outcome and for planning of future large-scale study
User satisfaction of ResearchApp
Participants will be invited to complete optional survey on user satisfaction of ResearchApp
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Leicester
Lead sponsor
NHS National Waiting Times Centre Board
Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborator
Oxford University Hospitals NHS Trust
Collaborator
Hull University Teaching Hospitals NHS Trust
Collaborator
University Hospitals Bristol and Weston NHS Foundation Trust
Collaborator
University Hospitals, Leicester
Collaborator
Royal Brompton & Harefield NHS Foundation Trust
Collaborator
King's College Hospital NHS Trust
Collaborator
University Hospital Plymouth NHS Trust
Collaborator